Press Release CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 8 hours ago
Press Release CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results Aug 3